Cantor’s Louise Chen: Valeant will look more interesting as long-term investment.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and its team are raring to continue the rebounding recovery of the once beleaguered biotech giant, and for …
Cantor’s Louise Chen believes Valeant will surpass $8 billion in sales in 2018, and says the set-up for the rebounding giant “keeps getting better” following Lumify’s approval.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that its affiliate has completed the divestiture of the Sprout Pharmaceuticals subsidiary to Sprout2 Inc., an entity …
This 50 billion-dollar fund is dropping VRX and turning to TEVA.
Mizuho’s Irina Rivkind Koffler cannot “justify” changing her rating on Valeant. Instead, the analyst lifts her price target by 40%; Here’s why.
J.P.
Why this Wall Street hedge fund legend sold VRX and GILD?
This billion-dollar hedge fund initiates new position in struggling pharma TEVA as exits VRX.
Is Billionaire fund guru Jim Simons switching OPK for VRX?
